BCM
ADVM

Bluefin Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Bluefin Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,700
Closed -$87K – 422
2019
Q4 		$87K Buy
+4,700
New +$414K 0.01% 424

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bluefin Capital Management's ADVM Position: Q1 2020 in Review

Bluefin Capital Management sold out of Adverum Biotechnologies (ADVM) in Q1 2020, closing a stake of 9,527 shares — an estimated $1.1M sold.

Bluefin Capital Management first reported a position in ADVM in Q3 2019 and held it in 2 quarters. The position peaked at $1.1M in Q4 2019. 126 funds tracked by Wall St. Rank hold ADVM as of Q1 2020.

  • Bluefin Capital Management reported no remaining Adverum Biotechnologies position as of Q1 2020 after selling out during the quarter.
  • Bluefin Capital Management sold 9,527 Adverum Biotechnologies shares in Q1 2020, an estimated $1.1M.
  • Bluefin Capital Management first reported a position in Adverum Biotechnologies in Q3 2019 and held it in 2 quarters.
  • Bluefin Capital Management's Adverum Biotechnologies position peaked at $1.1M in Q4 2019.
  • 126 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2020.

Based on Bluefin Capital Management's 13F filing for Q1 2020, filed 15 May 2020.